Genetically modified bacterium
Genetically modified bacteria were the first organisms to be modified in the laboratory, due to their simple genetics. These organisms are now used for several purposes, and are particularly important in producing large amounts of pure human proteins for use in medicine.
The first example of this occurred in 1978 when Herbert Boyer, working at a University of California laboratory, took a version of the human insulin gene and inserted into the bacterium Escherichia coli to produce synthetic "human" insulin. Four years later, it was approved by the U.S. Food and Drug Administration.
The drug industry has made use of this discovery to produce medication for diabetes. Similar bacteria have been used to produce clotting factors to treat haemophilia, and human growth hormone to treat various forms of dwarfism. These recombinant proteins are safer than the products they replaced. Prior to recombinant protein products, several treatments were derived from cadavers or other donated body fluids and could transmit diseases. Indeed, transfusion of blood products had previously led to unintentional infection of haemophiliacs with HIV or hepatitis C; similarly, treatment with human growth hormone derived from cadaver pituitary glands may have led to outbreaks of Creutzfeldt–Jakob disease.
Genetically modified bacteria can serve various purposes beyond producing medicinal compounds. For instance, bacteria which generally cause tooth decay have been engineered to no longer produce tooth-corroding lactic acid. These transgenic bacteria, if allowed to colonize a person's mouth, could perhaps reduce the formation of cavities. Transgenic microbes have also been used in recent research to kill or hinder tumors, and to fight Crohn's disease. Genetically modified bacteria are also used in some soils to facilitate crop growth, and can also produce chemicals toxic to crop pests.
Bacteria-synthesized transgenic products
- Hepatitis B vaccine
- Tissue plasminogen activator
- Human growth hormone
- Ice-minus bacteria
- Bt corn
- Terraforming § Other possibilities
- Melo EO, Canavessi AM, Franco MM, Rumpf R (2007). "Animal transgenesis: state of the art and applications" (PDF). Journal of Applied Genetics. 48 (1): 47–61. PMID 17272861. doi:10.1007/BF03194657. Archived from the original (PDF) on 27 September 2009.
- Leader B, Baca QJ, Golan DE (January 2008). "Protein therapeutics: a summary and pharmacological classification". Nature Reviews. Drug Discovery. A guide to drug discovery. 7 (1): 21–39. PMID 18097458. doi:10.1038/nrd2399.
- Walsh G (April 2005). "Therapeutic insulins and their large-scale manufacture". Applied Microbiology and Biotechnology. 67 (2): 151–9. PMID 15580495. doi:10.1007/s00253-004-1809-x.
- Pipe SW (May 2008). "Recombinant clotting factors". Thrombosis and Haemostasis. 99 (5): 840–50. PMID 18449413. doi:10.1160/TH07-10-0593.
- Bryant J, Baxter L, Cave CB, Milne R (July 2007). "Recombinant growth hormone for idiopathic short stature in children and adolescents". The Cochrane Database of Systematic Reviews (3): CD004440. PMID 17636758. doi:10.1002/14651858.CD004440.pub2.
- Baxter L, Bryant J, Cave CB, Milne R (January 2007). "Recombinant growth hormone for children and adolescents with Turner syndrome". The Cochrane Database of Systematic Reviews (1): CD003887. PMID 17253498. doi:10.1002/14651858.CD003887.pub2.
- Foster PR (October 2000). "Prions and blood products". Annals of Medicine. 32 (7): 501–13. PMID 11087171. doi:10.3109/07853890009002026.
- Key NS, Negrier C (August 2007). "Coagulation factor concentrates: past, present, and future". Lancet. 370 (9585): 439–48. PMID 17679021. doi:10.1016/S0140-6736(07)61199-4.
- Hillman JD (August 2002). "Genetically modified Streptococcus mutans for the prevention of dental caries". Antonie Van Leeuwenhoek. 82 (1-4): 361–6. PMID 12369203. doi:10.1023/A:1020695902160.
- Hillman JD, Mo J, McDonell E, Cvitkovitch D, Hillman CH (May 2007). "Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials". Journal of Applied Microbiology. 102 (5): 1209–19. PMID 17448156. doi:10.1111/j.1365-2672.2007.03316.x.
- Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L (June 2006). "A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease". Clinical Gastroenterology and Hepatology. 4 (6): 754–9. PMID 16716759. doi:10.1016/j.cgh.2006.03.028.
- Valda D, Dowling J (10 December 2010). "Making Microbes Better Miners". Business Chile Magazine. Retrieved 21 March 2012.
- Ruiz ON, Alvarez D, Gonzalez-Ruiz G, Torres C (August 2011). "Characterization of mercury bioremediation by transgenic bacteria expressing metallothionein and polyphosphate kinase". BMC Biotechnology. 11: 82. PMC . PMID 21838857. doi:10.1186/1472-6750-11-82.
- Sanderson K (24 February 2012). "New Portable Kit Detects Arsenic In Wells". Chemical and Engineering News.